🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 21 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 04/10/2012 | 58,03 | 59,65 | 58,00 | 59,39 | +2,82% | 2,84% | 2.259.400 |
| 03/10/2012 | 57,42 | 58,15 | 57,37 | 57,76 | +0,84% | 1,36% | 1.483.300 |
| 02/10/2012 | 57,05 | 57,89 | 56,60 | 57,28 | +1,49% | 2,26% | 2.020.000 |
| 01/10/2012 | 55,92 | 57,02 | 55,47 | 56,44 | +0,98% | 2,77% | 2.556.600 |
| 28/09/2012 | 55,58 | 56,88 | 55,06 | 55,89 | +0,41% | 3,27% | 1.595.200 |
| 27/09/2012 | 54,73 | 56,03 | 54,19 | 55,66 | +1,62% | 3,36% | 1.485.300 |
| 26/09/2012 | 56,13 | 56,46 | 54,62 | 54,77 | -2,65% | 3,28% | 1.937.200 |
| 25/09/2012 | 58,99 | 59,05 | 56,11 | 56,26 | -4,19% | 4,98% | 2.383.200 |
| 24/09/2012 | 59,00 | 59,98 | 58,26 | 58,72 | -0,54% | 2,92% | 2.330.400 |
| 21/09/2012 | 58,19 | 59,50 | 57,49 | 59,04 | +1,57% | 3,45% | 3.616.300 |
| 20/09/2012 | 57,58 | 58,77 | 57,01 | 58,13 | +0,40% | 3,06% | 1.227.600 |
| 19/09/2012 | 57,51 | 58,13 | 57,03 | 57,90 | +0,78% | 1,91% | 1.219.400 |
| 18/09/2012 | 57,33 | 58,15 | 56,99 | 57,45 | -0,16% | 2,02% | 1.085.700 |
| 17/09/2012 | 57,50 | 57,98 | 57,23 | 57,54 | -0,93% | 1,30% | 1.204.300 |
| 14/09/2012 | 56,32 | 58,22 | 56,32 | 58,08 | +3,33% | 3,37% | 1.482.200 |
| 13/09/2012 | 55,98 | 57,08 | 55,17 | 56,21 | +0,84% | 3,41% | 1.416.400 |
| 12/09/2012 | 56,37 | 56,74 | 55,28 | 55,74 | -0,55% | 2,59% | 840.700 |
| 11/09/2012 | 56,63 | 56,64 | 55,66 | 56,05 | -1,04% | 1,73% | 829.500 |
| 10/09/2012 | 57,71 | 57,99 | 56,40 | 56,64 | -0,81% | 2,76% | 632.300 |
| 07/09/2012 | 57,27 | 57,58 | 56,31 | 57,10 | -0,59% | 2,22% | 908.900 |
| 06/09/2012 | 55,05 | 57,92 | 54,81 | 57,44 | +4,46% | 5,65% | 1.876.200 |
| 05/09/2012 | 54,43 | 55,49 | 54,06 | 54,99 | +0,84% | 2,63% | 1.654.500 |
| 04/09/2012 | 53,30 | 54,86 | 52,63 | 54,53 | +2,25% | 4,18% | 1.365.800 |
| 31/08/2012 | 53,73 | 54,27 | 52,73 | 53,33 | +0,09% | 2,87% | 890.300 |
| 30/08/2012 | 53,21 | 53,80 | 52,93 | 53,28 | -0,08% | 1,64% | 1.216.300 |
| 29/08/2012 | 54,00 | 54,67 | 52,79 | 53,32 | -1,42% | 3,48% | 2.158.100 |
| 28/08/2012 | 53,51 | 54,42 | 52,75 | 54,09 | +1,08% | 3,12% | 1.864.100 |
| 27/08/2012 | 53,86 | 54,50 | 53,18 | 53,51 | -0,09% | 2,45% | 1.332.000 |
| 24/08/2012 | 53,99 | 54,81 | 53,46 | 53,56 | -0,58% | 2,50% | 1.031.600 |
| 23/08/2012 | 54,51 | 54,66 | 53,57 | 53,87 | -1,46% | 2,00% | 1.084.500 |